Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2009 3
2010 7
2011 11
2012 6
2013 10
2014 5
2015 8
2016 10
2017 9
2018 12
2019 11
2020 6
2021 10
2022 12
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Molecular methods for serovar determination of Salmonella.
Shi C, Singh P, Ranieri ML, Wiedmann M, Moreno Switt AI. Shi C, et al. Crit Rev Microbiol. 2015;41(3):309-25. doi: 10.3109/1040841X.2013.837862. Epub 2013 Nov 14. Crit Rev Microbiol. 2015. PMID: 24228625 Review.
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
Chu T, Yuan J, Lu J, Nie W, Zhong R, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Zhang X, Teng J, Gao Z, Lou Y, Li J, Qiang H, Zhang C, Li J, Xia X, Zhong H, Han B. Chu T, et al. Among authors: shi c. Clin Transl Med. 2023 Jun;13(6):e1277. doi: 10.1002/ctm2.1277. Clin Transl Med. 2023. PMID: 37254636 Free PMC article. No abstract available.
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer.
Zhang W, Wang J, Wang Q, Cheng Y, Yang L, Li Y, Zhong H, Chu T, Dong Y, Zhang Y, Qian F, Xiong L, Shi C, Zhang C, He Z, Zhu J, Liu X, Ma H, Li K, Han B. Zhang W, et al. Among authors: shi c. Lung Cancer. 2023 Oct;184:107353. doi: 10.1016/j.lungcan.2023.107353. Epub 2023 Aug 21. Lung Cancer. 2023. PMID: 37647728 Free article. Clinical Trial.
Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study).
Zhang B, Zhong H, Shi C, Gao Z, Zhong R, Gu A, Wang W, Chu T, Xiong L, Zhang W, Wang H, Zhang X, Han B. Zhang B, et al. Among authors: shi c. Clin Respir J. 2023 Dec;17(12):1361-1367. doi: 10.1111/crj.13715. Epub 2023 Nov 10. Clin Respir J. 2023. PMID: 37947242 Free PMC article. Clinical Trial.
113 results